All Stories

  1. Stress-conditioned small extracellular vesicles from young cells to restore resilience in aging
  2. The Phospholipid Bis(monoacylglycero)Phosphate Confers Antitumour Immunogenicity to Exosomes Secreted by Dendrogenin A, Which Activates Its Biosynthesis in Tumour Cells
  3. 5,6-Epoxycholestanols Metabolism and Functions: Defining the Epoxycholestanoid (EChA) Family
  4. Liver X receptors and the hallmarks of aging: From molecular mechanisms to therapeutic opportunities
  5. Liver X Receptors and the Hallmarks of Aging: From Molecular Mechanisms to Therapeutic Opportunities
  6. Oxysterols at the Crossroads of Cholesterol Metabolism and Cancer
  7. Liver X Receptors and the Hallmarks of Aging: From Molecular Mechanisms to Therapeutic Opportunities
  8. Current advances in phytosterol free forms and esters: Classification, biosynthesis, chemistry, and detection
  9. 11th ENOR meeting: Oxysterols in human health and diseases
  10. Editorial: Lipids, lipid oxidation, and cancer: from biology to therapeutics
  11. The Cholesterol-5,6-Epoxide Hydrolase: A Metabolic Checkpoint in Several Diseases
  12. 27-Hydroxylation of oncosterone by CYP27A1 switches its activity from pro-tumor to anti-tumor
  13. Chemical synthesis and biochemical properties of cholestane-5α,6β-diol-3-sulfonate: A non-hydrolysable analogue of cholestane-5α,6β-diol-3β-sulfate
  14. 27-hydroxylation of oncosterone by CYP27A1 switchs its activity from pro-tumor to anti-tumor
  15. Is cholesterol a risk factor for breast cancer incidence and outcome?
  16. European Network for oxysterol research (ENOR): 10th ENOR symposium – Web meeting
  17. An Update on Tamoxifen and the Chemo-Preventive Potential of Vitamin E in Breast Cancer Management
  18. Vitamin E components give a multitude of oxidation products.
  19. Targeting NR1H/liver X receptor with dendrogenin A differentiates tumor cells to activate a new secretory pathway releasing immunogenic anti-tumor vesicles enriched in LC3-II-associated exosomes
  20. Celebrating the 10th anniversary of the creation of the European Network for Oxysterol Research (ENOR)
  21. Cholesterol is a lipid producing signaling molecules controlling Aging
  22. Targeting the liver X receptor with dendrogenin A differentiates tumour cells to secrete immunogenic exosome‐enriched vesicles
  23. Pharmacologic and genetic inhibition of cholesterol esterification enzymes reduces tumour burden: A systematic review and meta-analysis of preclinical models
  24. Sterol metabolism and cancer
  25. Acknowledgement to Reviewers of Immunometabolism in 2021
  26. European network for oxysterol research (ENOR): 10 th anniversary
  27. Pharmacologic and genetic inhibition of cholesterol esterification reduces tumour burden: a pan-cancer systematic review and meta-analysis of preclinical models
  28. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
  29. Dendrogenin A Enhances Anti-Leukemic Effect of Anthracycline in Acute Myeloid Leukemia
  30. The 5,6‐epoxycholesterol metabolic pathway in breast cancer: Emergence of new pharmacological targets
  31. Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo
  32. The 5,6-epoxycholesterol metabolic pathway in cancer: emergence of new pharmacological targets
  33. Oxysterols and sterols: From lipidomics to food sciences
  34. Vitamin E: an overview
  35. A fast UPLC–HILIC method for an accurate quantification of dendrogenin A in human tissues
  36. Oxysterols: An expanding family of structurally diversified bioactive steroids
  37. The cholesterol-derived metabolite dendrogenin A functionally reprograms breast adenocarcinoma and undifferentiated thyroid cancer cells
  38. Flavonoids differentially modulate liver X receptors activity—Structure-function relationship analysis
  39. Natural and semisynthetic oxyprenylated aromatic compounds as stimulators or inhibitors of melanogenesis
  40. HPLC Analysis and Skin Whitening Effects of Umbelliprenin-containing Extracts of Anethum Graveolens, Pimpinella Anisum, and Ferulago Campestris
  41. Chemistry, biochemistry, metabolic fate and mechanism of action of 6-oxo-cholestan-3β,5α-diol (OCDO), a tumor promoter and cholesterol metabolite
  42. The Effects of Cholesterol-Derived Oncometabolites on Nuclear Receptor Function in Cancer
  43. Extracellular vesicles: lipids as key components of their biogenesis and functions
  44. The tumor-suppressor cholesterol metabolite, dendrogenin A, is a new class of LXR modulator activating lethal autophagy in cancers
  45. Abstract 5238: Characterization of the enzyme generating the cholesterol metabolite and tumor suppressor dendrogenin A in the breast and its deregulations in breast cancer
  46. Ligand-dependent transcriptional induction of lethal autophagy: A new perspective for cancer treatment
  47. Bryonolic Acid Blocks Cancer Cell Clonogenicity and Invasiveness through the Inhibition of Fatty Acid: Cholesteryl Ester Formation
  48. Meet Our Editorial Board Member
  49. Dendrogenin A (DDA) is a cholesterol metabolite with potent anticancer properties
  50. Improving the efficacy of hormone therapy in breast cancer: The role of cholesterol metabolism in SERM-mediated autophagy, cell differentiation and death
  51. Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor
  52. Quantitative analysis of the tumor suppressor dendrogenin A using liquid chromatography tandem mass spectrometry
  53. Improvement of 5,6α-epoxycholesterol, 5,6β-epoxycholesterol, cholestane-3β,5α,6β-triol and 6-oxo-cholestan-3β,5α-diol recovery for quantification by GC/MS
  54. Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study
  55. From tamoxifen to dendrogenin A: The discovery of a mammalian tumor suppressor and cholesterol metabolite
  56. When cholesterol meets histamine, it gives rise to dendrogenin A: a tumour suppressor metabolite1
  57. Erratum
  58. Molecular and Biochemical Analysis of the Estrogenic and Proliferative Properties of Vitamin E Compounds
  59. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
  60. dendrogenin A: a good cholesterol metabolite against cancer
  61. Abstract 1165: Identification of a cholesterol onco-metabolite, promoter of tumor in breast cancers, and of the enzyme involved in its biosynthesis
  62. Dendrogenin A and B two new steroidal alkaloids increasing neural responsiveness in the deafened guinea pig
  63. Cholesterol metabolites exported from human brain
  64. Abstract P3-05-12: Circulating oxysterol metabolites as potential new surrogate markers for hormonotherapy in patients with hormone receptor-positive breast cancer? A pilot study
  65. Dendrogenin_A : A Natural Liver X Receptor Modulator for the Treatment of Acute Myeloid Leukemia
  66. The fatal ADORAtion of adenosine based cyclic dinucleotides
  67. One step synthesis of 6-oxo-cholestan-3β,5α-diol
  68. The novel steroidal alkaloids dendrogenin A and B promote proliferation of adult neural stem cells
  69. Cholesterol and Cancer, in the Balance
  70. Emerging concepts on the role of exosomes in lipid metabolic diseases
  71. Exosomes as new vesicular lipid transporters involved in cell–cell communication and various pathophysiologies
  72. Generation of whole-body scintigraphic images with new GATE output capacities
  73. Progesterone and a phospholipase inhibitor increase the endosomal bis(monoacylglycero)phosphate content and block HIV viral particle intercellular transmission
  74. 5,6-Epoxy-cholesterols contribute to the anticancer pharmacology of Tamoxifen in breast cancer cells
  75. Oxysterols and related sterols: Implications in pharmacology and pathophysiology
  76. Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism
  77. Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties
  78. Improved realism of hybrid mouse models may not be sufficient to generate reference dosimetric data
  79. Abstract 1662: Dendrogenin A is a newly identified mammalian steroidal alkaloid that induced autophagic cell death in melanoma cells through an LXRbeta-, Nur77- and Nor1-dependent way.
  80. Cholesterol-5,6-epoxides: Chemistry, biochemistry, metabolic fate and cancer
  81. Technical note: Hapten synthesis, antibody production and development of an enzyme-linked immunosorbent assay for detection of the natural steroidal alkaloid Dendrogenin A
  82. Cholesterol epoxide hydrolase and cancer
  83. Cholesterol metabolism and cancer: the good, the bad and the ugly
  84. Cholesterol metabolism and resistance to tamoxifen
  85. MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy
  86. Guidelines for the use and interpretation of assays for monitoring autophagy
  87. Abstract 956: The liver-X-receptor-α is involved in the induction by Tamoxifen of breast cancer cell differentiation and death
  88. Identification of a new stilbene-derived inducer of paraoxonase 1 and ligand of the Aryl hydrocarbon Receptor
  89. Surprising unreactivity of cholesterol-5,6-epoxides towards nucleophiles
  90. Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands
  91. Exosomes as intercellular signalosomes and pharmacological effectors
  92. Abstract 938: Discovery of Dendrogenin A as the first endogenous alkylaminooxysterol present in mammals with potent cell differentiation and anticancer activity
  93. Four decades of discovery in breast cancer research and treatment an interview with V. Craig Jordan
  94. R42 – Oral Un « bon et mauvais cholestérol » pour la thérapie et dans la pathophysiologie des cancers : les cholestérols époxydes et leurs dérivés sous les feux de la rampe
  95. R44: Médiateurs lipidiques et cancer : les exosomes comme « signalosomes » intercellulaires transporteurs de prostaglandines
  96. R167 - Oral, Club Mex-H Quantification du volume tumoral résiduel des cancers du rectum post-radiochimiothérapie par histomorphométrie quantitative
  97. R92: Intérêt de la modélisation moléculaire dans le développement de nouveaux radiopharmaceutiques en oncologie nucléaire
  98. Auraptene Is an Inhibitor of Cholesterol Esterification and a Modulator of Estrogen Receptors
  99. Correction for de Medina et al., Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands
  100. Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands
  101. Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: From molecular modeling to in vivo evaluation
  102. Ciblage peptidique en oncologie nucléaire : intérêt de la modélisation moléculaire
  103. Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins
  104. Abstract 2918: Molecular identification of the cholesterol-5,6-epoxide hydrolase: A new target for selective estrogen receptor modulators and unsaturated fatty acids
  105. Synthesis, characterization and in vitro evaluation of new oxorhenium- and oxotechnetium-CCK4 derivatives as molecular imaging agents for CCK2-receptor targeting
  106. Synthesis of New Alkylaminooxysterols with Potent Cell Differentiating Activities: Identification of Leads for the Treatment of Cancer and Neurodegenerative Diseases
  107. Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation
  108. Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism
  109. Signaling through cholesterol esterification: a new pathway for the cholecystokinin 2 receptor involved in cell growth and invasion
  110. Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism
  111. Structure-based identification of ER and ACAT as molecular targets involved in the chemopreventive activity of the citrus auraptene
  112. Preclinical evaluation of new radioligand of cholecystokinin/gastrin receptors in endocrine tumors xenograft nude mice
  113. Insights into the Cholecystokinin 2 Receptor Binding Site and Processes of Activation
  114. The Prototypical Inhibitor of Cholesterol Esterification, Sah 58-035 [3-[Decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenylethyl]propanamide], Is an Agonist of Estrogen Receptors
  115. Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways
  116. Synthesis and Biological Properties of New Stilbene Derivatives of Resveratrol as New Selective Aryl Hydrocarbon Modulators
  117. Multiple Targeting by the Antitumor Drug Tamoxifen: A Structure-Activity Study
  118. Molecular Characterization of the Microsomal Tamoxifen Binding Site
  119. Tamoxifen Is a Potent Inhibitor of Cholesterol Esterification and Prevents the Formation of Foam Cells
  120. High tumorigenic potential of a constitutively active mutant of the cholecystokinin 2 receptor
  121. Identification of Tyrosine 189 and Asparagine 358 of the Cholecystokinin 2 Receptor in Direct Interaction with the Crucial C-Terminal Amide of Cholecystokinin by Molecular Modeling, Site-Directed Mutagenesis, and Structure/Affinity Studies
  122. Contrasting Effects of Prenyltransferase Inhibitors on Estrogen-Dependent Cell Cycle Progression and Estrogen Receptor-Mediated Transcriptional Activity in MCF-7 Cells
  123. Insulin and estrogen receptor ligand influence the FGF-2 activities in MCF-7 breast cancer cells
  124. Identification of Two Tamoxifen Target Proteins by Photolabeling with 4-(2-Morpholinoethoxy)benzophenone
  125. Alteration of plasmalemmal caveolae mimics endothelial dysfunction observed in atheromatous rabbit aorta
  126. Synthesis, binding and structure–affinity studies of new ligands for the microsomal anti-estrogen binding site (AEBS)
  127. Structural similitudes between cytotoxic antiestrogen-binding site (AEBS) ligands and cytotoxic sigma receptor ligands. evidence for a relationship between cytotoxicity and affinity for AEBS or sigma-2 receptor but not for sigma-1 receptor
  128. Modifications of benzylphenoxy ethanamine antiestrogen molecules: influence affinity for antiestrogen binding site (AEBS) and cell cytotoxicity
  129. Different populations of progesterone receptor–steroid complexes in binding to specific DNA sequences: effects of salts on kinetics and specificity
  130. Microsomal epoxide hydrolase of rat liver is a subunit of theanti-oestrogen-binding site
  131. Characterization of the Membranous Antiestrogen Binding Protein: I Partial purification of the protein in its active state
  132. Characterization of the Membranous Antiestrogen Binding Protein: II Purification to homogeneity
  133. Characterization of a benzyl-phenoxy-ethanamine binding protein in Trypanosoma equiperdum and the possible relation between binding affinity and trypanocidal activity
  134. Cytosolic Type II Estrogen Binding Site in Rat Uterus: Specific Photolabeling with Estrone
  135. The anti-proliferative properties of 4-benzylphenoxy ethanamine derivatives are mediated by the anti-estrogen binding site (ABS), whereas the anti-estrogenic effects of trifluopromazine are not
  136. Further evidence for a biological role of anti-estrogen-binding sites in mediating the growth inhibitory action of diphenylmethane derivatives